Shares of Monogram Technologies (NASDAQ:MGRM) jumped 60% following news that Zimmer Biomet (NYSE:ZBH) has agreed to acquire the orthopedic robotics firm in a deal valued at approximately $177 million in equity.
Per the agreement, Zimmer Biomet will purchase all outstanding Monogram shares for $4.04 in cash each. In addition, Monogram shareholders will receive a non-tradeable contingent value right (CVR), which could be worth as much as $12.37 per share if a series of development, regulatory, and revenue milestones are met by 2030.
The acquisition is designed to enhance Zimmer Biomet’s ROSA Robotics platform by integrating Monogram’s advanced robotic solutions, including both semi- and fully autonomous systems. Monogram’s CT-based, semi-autonomous, AI-driven total knee arthroplasty robotic system received FDA 510(k) clearance in March 2025. That technology is expected to launch commercially in early 2027, utilizing Zimmer Biomet implants.
“Monogram’s technology is a major leap forward, demonstrating our commitment to becoming the boldest and broadest innovator in surgical robotics and navigation,” said Ivan Tornos, Chairman, President and CEO of Zimmer Biomet.
Zimmer Biomet anticipates the acquisition will be earnings-neutral from 2025 through 2027 and accretive thereafter. The company expects revenue contributions to begin in 2027, with a high-single-digit return on invested capital projected by year five.
The boards of both companies have unanimously approved the transaction, which is still subject to approval from regulators and Monogram shareholders, along with other customary closing requirements. The deal is expected to close before the end of the year.
Monogram Technologies stock price
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.